The Surveillance Error Grid: A credible metric for assessing the clinical accuracy of blood glucose monitors

 

The Surveillance Error Grid

From Journal of Diabetes Science and Technology

In the United States, the Food and Drug Administration (FDA) and blood glucose (BG) monitor manufacturers perform surveillance to monitor the performance of glucose monitors in use by patients and health care providers. Currently used error grids for assessing clinical accuracy of blood glucose monitors are based on out-of-date medical practices. Diabetes Technology Society together with representatives from the Food and Drug Administration, the American Diabetes Association, the Endocrine Society, and the Association for the Advancement of Medical Instrumentation, and representatives of academia, industry, and government, have developed a new error grid, called the surveillance error grid (SEG) as a tool to assess the degree of clinical risk from inaccurate blood glucose (BG) monitors.

The SEG is intended to assist regulatory authorities and manufacturers in assessing the risks resulting from BG monitoring systems that are on the market but encounter problems in the postmarket environment (eg, monitors that are reported to have contributed to adverse events, or are under recall). The incorporation of input from over 200 diabetes clinicians and the analysis of the clinicians’ survey results by the 33 authors of this article render this new tool to be a timely and credible consensus metric for assessing the clinical accuracy of BG monitors. It is expected that if the application of this consensus surveillance grid proves to be useful for assessing BG monitors, then this approach can be applied in the future to other measuring devices.

Abstract

Currently used error grids for assessing clinical accuracy of blood glucose monitors are based on out-of-date medical practices. Error grids have not been widely embraced by regulatory agencies for clearance of monitors, but this type of tool could be useful for surveillance of the performance of cleared products. Diabetes Technology Society together with representatives from the Food and Drug Administration, the American Diabetes Association, the Endocrine Society, and the Association for the Advancement of Medical Instrumentation, and representatives of academia, industry, and government, have developed a new error grid, called the surveillance error grid (SEG) as a tool to assess the degree of clinical risk from inaccurate blood glucose (BG) monitors. A total of 206 diabetes clinicians were surveyed about the clinical risk of errors of measured BG levels by a monitor. The impact of such errors on 4 patient scenarios was surveyed. Each monitor/reference data pair was scored and color-coded on a graph per its average risk rating. Using modeled data representative of the accuracy of contemporary meters, the relationships between clinical risk and monitor error were calculated for the Clarke error grid (CEG), Parkes error grid (PEG), and SEG. SEG action boundaries were consistent across scenarios, regardless of whether the patient was type 1 or type 2 or using insulin or not. No significant differences were noted between responses of adult/pediatric or 4 types of clinicians. Although small specific differences in risk boundaries between US and non-US clinicians were noted, the panel felt they did not justify separate grids for these 2 types of clinicians. The data points of the SEG were classified in 15 zones according to their assigned level of risk, which allowed for comparisons with the classic CEG and PEG. Modeled glucose monitor data with realistic self-monitoring of blood glucose errors derived from meter testing experiments plotted on the SEG when compared to the data plotted on the CEG and PEG produced risk estimates that were more granular and reflective of a continuously increasing risk scale. The SEG is a modern metric for clinical risk assessments of BG monitor errors that assigns a unique risk score to each monitor data point when compared to a reference value. The SEG allows the clinical accuracy of a BG monitor to be portrayed in many ways, including as the percentages of data points falling into custom-defined risk zones. For modeled data the SEG, compared with the CEG and PEG, allows greater precision for quantifying risk, especially when the risks are low. This tool will be useful to allow regulators and manufacturers to monitor and evaluate glucose monitor performance in their surveillance programs.

 

Read this article for free

Article details
David C. Klonoff, Courty Lias, Robert Vigersky, William Clarke, Joan Lee Parkes, David B. Sacks, M. Sue Kirkman, Boris Kovatchev, and the Error Grid Panel
The Surveillance Error Grid J Diabetes Sci Technol July 2014 8: 658-672, first published on June 13, 2014 doi:10.1177/1932296814539589

 

 

 

 

     
This entry was posted in Medicine, SAGE Insight and tagged , , , . Bookmark the permalink.